NEW YORK, March 24 - Cambridge, Mass.-based bioinformatics firm Biosift said today that it has acquired Entigen's intellectual property and technology assets, which have been in a state of suspension since Entigen closed its offices last March.
Biosift purchased rights to Entigen's BioNavigator genomics portal and Adaapt data integration technology. These tools will be integrated with Biosift's Radia sequence analysis package and Scintilla genome browser.
Entigen was formed in December 2000 by the merger of bioinformatics ASP eBioinformatics and integration technology provider Empatheon. It maintained offices in Sydney, Australia, and Sunnyvale, Calif., before shutting its doors a year ago following an unsuccessful attempt to raise additional funding.
Bala Manian, chairman of the board at Entigen, told GenomeWeb.com's sister publication BioInform last April that the company's tools and assets were "being held in abeyance" while he sought a buyer for the technology.
"The company's not closed down," he said at the time, noting that he hoped to sell the technology in one piece rather than split it between several buyers.